Compare Nuwellis Inc (NUWE) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Xpeng Inc - ADR — how do they compare? Nuwellis Inc trades at $0.7 (market cap $2.20M), while Xpeng Inc - ADR trades at $9.97 (market cap $9.16B). The key difference: Xpeng Inc - ADR is far larger — about 4163.6× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 5,030,325). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Xpeng Inc - ADR for 80 Days on average.
| NUWE | XPEV | |
|---|---|---|
Market Cap | $2.20M | $9.16B |
Volume | 121,544 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $28.07 |
52-Week Low | $0.68 | $9.25 |
Typical Hold Time | 26 Days | 80 Days |
Enterprise Value | -$1.52M | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
XPeng (XPEV) trades at $9.58, up 0.21% today, with a bearish technical signal despite oversold RSI readings. The company reported strong Q4 2025 earnings beat but missed Q1 and Q2 2026 expectations. Revenue grew to $76.72B in 2025, with net losses narrowing to -$1.14B. Recent news highlights XPeng's expansion into humanoid robotics and global vehicle launches, including the G9L SUV debut at the Paris Motor Show.
XPeng shows improving revenue growth and narrowing losses, but persistent unprofitability and high EV/EBITDA of 144.25 pose valuation concerns. Analyst consensus is bullish with a $17.55 price target, though execution risks in new robotics ventures and competitive EV market pressures remain key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
